Meribank Biotech Co Ltd(TW:4724)
NT$9.12-0.13 (-1.41%)
TW:4724
Meribank Biotech Co Ltd financials statements
NT$9.12
At close:-0.13 (-1.41%)
Meribank Biotech Co Ltd (4724) Ratios
Meribank Biotech Co Ltd Ratios
TW:4724's free cash flow for Q2 2026 was NT$27.57M. For the 2026 fiscal year, TW:4724's free cash flow was decreased by NT$-8.78M and operating cash flow was NT$36.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.90 | 1.69 | 4.49 | 3.60 | 4.79 |
| Quick Ratio | 1.88 | 1.65 | 4.44 | 3.52 | 4.75 |
| Cash Ratio | 0.39 | 0.71 | 3.15 | 0.78 | 2.00 |
| Solvency Ratio | 0.05 | -0.01 | -0.23 | -0.19 | -0.19 |
| Operating Cash Flow Ratio | 0.36 | -0.16 | -0.23 | -0.38 | -0.24 |
| Short-Term Operating Cash Flow Coverage | 11.98 | -5.20 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ -1.15B | NT$ -1.07B | NT$ 179.37M | NT$ 20.36M | NT$ 97.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.39 | 0.35 | 0.03 | 0.05 | 0.06 |
| Debt-to-Equity Ratio | 0.90 | 0.78 | 0.05 | 0.10 | 0.09 |
| Debt-to-Capital Ratio | 0.47 | 0.44 | 0.05 | 0.09 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.12 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.30 | 2.22 | 1.60 | 1.80 | 1.62 |
| Debt Service Coverage Ratio | 3.58 | -0.12 | -108.76 | -65.56 | -60.92 |
| Interest Coverage Ratio | -2.28 | -8.10 | -145.40 | -111.45 | -86.34 |
| Debt to Market Cap | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 12.60 | 11.98 | 0.55 | 0.74 | 0.89 |
| Net Debt to EBITDA | 10.04 | -113.92 | 3.95 | 0.61 | 2.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.86% | 52.93% | 59.26% | 52.61% | 55.22% |
| EBIT Margin | -11.19% | -24.79% | -55.09% | -53.75% | -60.14% |
| EBITDA Margin | 21.76% | -1.86% | -39.50% | -35.90% | -42.07% |
| Operating Profit Margin | -11.19% | -23.65% | -52.55% | -60.95% | -59.62% |
| Pretax Profit Margin | -18.85% | -27.71% | -55.45% | -57.31% | -60.83% |
| Net Profit Margin | -17.27% | -25.85% | -53.49% | -56.70% | -60.83% |
| Continuous Operations Profit Margin | -17.42% | -26.45% | -55.26% | -57.27% | -60.83% |
| Net Income Per EBT | 91.60% | 93.27% | 96.46% | 98.94% | 100.00% |
| EBT Per EBIT | 168.50% | 117.16% | 105.52% | 94.03% | 102.03% |
| Return on Assets (ROA) | -2.83% | -3.53% | -11.80% | -12.07% | -10.47% |
| Return on Equity (ROE) | -6.52% | -7.86% | -18.94% | -21.68% | -16.93% |
| Return on Capital Employed (ROCE) | -2.01% | -3.54% | -13.17% | -14.89% | -11.42% |
| Return on Invested Capital (ROIC) | -1.76% | -3.27% | -12.86% | -14.46% | -11.18% |
| Return on Tangible Assets | -3.98% | -5.22% | -12.20% | -12.22% | -10.48% |
| Earnings Yield | -5.46% | -4.25% | -5.26% | -5.21% | -5.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.45 | 2.24 | 1.74 | 1.19 | 1.11 |
| Payables Turnover | 38.96 | 13.19 | 7.75 | 11.23 | 15.38 |
| Inventory Turnover | 41.97 | 15.34 | 13.82 | 10.11 | 20.26 |
| Fixed Asset Turnover | 1.00 | 0.76 | 1.45 | 1.01 | 0.85 |
| Asset Turnover | 0.16 | 0.14 | 0.22 | 0.21 | 0.17 |
| Working Capital Turnover Ratio | 2.46 | 1.21 | 0.64 | 0.56 | 0.63 |
| Cash Conversion Cycle | 148.55 | 159.25 | 188.88 | 311.23 | 324.49 |
| Days of Sales Outstanding | 149.22 | 163.13 | 209.56 | 307.61 | 330.21 |
| Days of Inventory Outstanding | 8.70 | 23.79 | 26.41 | 36.12 | 18.02 |
| Days of Payables Outstanding | 9.37 | 27.67 | 47.09 | 32.50 | 23.73 |
| Operating Cycle | 157.92 | 186.92 | 235.97 | 343.73 | 348.22 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.98 | -0.48 | -0.47 | -0.65 | -0.38 |
| Free Cash Flow Per Share | 0.93 | -4.80 | -0.58 | -0.72 | -0.50 |
| Dividend Paid and CapEx Coverage Ratio | 18.31 | -0.11 | -4.45 | -9.73 | -3.06 |
| Capital Expenditure Coverage Ratio | 18.31 | -0.11 | -4.45 | -9.73 | -3.06 |
| Operating Cash Flow Coverage Ratio | 0.08 | -0.04 | -0.87 | -0.90 | -0.43 |
| Operating Cash Flow to Sales Ratio | 0.19 | -0.10 | -0.13 | -0.23 | -0.14 |
| Free Cash Flow Yield | 5.66% | -17.15% | -1.53% | -2.33% | -1.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -18.37 | -23.53 | -19.02 | -19.14 | -19.02 |
| Price-to-Sales (P/S) Ratio | 3.17 | 6.08 | 10.17 | 10.87 | 11.59 |
| Price-to-Book (P/B) Ratio | 1.20 | 1.85 | 3.60 | 4.16 | 3.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 17.66 | -5.83 | -65.54 | -42.97 | -61.95 |
| Price-to-Operating Cash Flow Ratio | 16.69 | -58.51 | -80.28 | -47.39 | -82.21 |
| Price-to-Earnings Growth (PEG) Ratio | 0.73 | 0.59 | -0.83 | 31.19 | -0.32 |
| Enterprise Value Multiple | 24.59 | -440.35 | -21.81 | -29.68 | -25.53 |
| Enterprise Value | 2.52B | 3.01B | 2.02B | 1.92B | 1.75B |
| EV to EBITDA | 24.59 | -440.35 | -21.81 | -29.68 | -25.53 |
| EV to Sales | 5.35 | 8.20 | 8.61 | 10.66 | 10.74 |
| EV to Free Cash Flow | 29.84 | -7.86 | -55.49 | -42.11 | -57.39 |
| EV to Operating Cash Flow | 28.21 | -78.93 | -67.97 | -46.44 | -76.16 |
| Tangible Book Value Per Share | 4.73 | 4.41 | 10.11 | 7.34 | 9.59 |
| Shareholders’ Equity Per Share | 13.68 | 15.15 | 10.51 | 7.46 | 9.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.05 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 5.17 | 4.60 | 3.72 | 2.85 | 2.67 |
| Net Income Per Share | -0.89 | -1.19 | -1.99 | -1.62 | -1.63 |
| Tax Burden | 0.92 | 0.93 | 0.96 | 0.99 | 1.00 |
| Interest Burden | 1.69 | 1.12 | 1.01 | 1.07 | 1.01 |
| Research & Development to Revenue | 0.07 | 0.10 | 0.15 | 0.14 | 0.10 |
| SG&A to Revenue | 0.47 | 0.67 | 0.95 | 0.99 | 1.02 |
| Stock-Based Compensation to Revenue | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | -1.01 | 0.38 | 0.24 | 0.40 | 0.23 |
Currency in TWD
